Abstract:Background: The dabrafenib plus trametinib combination (DT) has revolutionized treatment of BRAFV600E-mutated anaplastic thyroid carcinoma (BRAFm-ATC). However, patients eventually develop resistance and progress. Single-agent anti-PD-1 inhibitor spartalizumab has shown a median overall survival (mOS) of 5.9 months. Combination of immunotherapy with BRAF/MEK inhibitors seems to improve outcomes compared to BRAF/MEK inhibitors alone, although no direct comparison is available. BRAF-targeted therapy prior to surgery (neoadjuvant approach) has also shown improvement in survival. We studied the efficacy and safety of DT plus pembrolizumab (DTP) compared to current standard of care DT alone as an initial treatment, as well as in the neoadjuvant setting. Methods: Retrospective single-center study of patients with BRAFm-ATC treated with first-line BRAF-directed therapy between 1/2014 and 3/2023. Three groups were evaluated: DT, DTP (pembrolizumab added upfront or at progression), and neoadjuvant (DT before surgery, and pembrolizumab added before or after surgery). Primary endpoint was mOS between DT and DTP. Secondary endpoints included median progression-free survival (mPFS) and response rate with DT vs DTP as initial treatments, and exploratory endpoint was mOS in neoadjuvant group. Results: 71 patients were included in the primary analysis: n=23 in DT, n=48 in DTP. Baseline demographics were similar between groups, including presence of metastatic disease at start of treatment (p=0.427) and prior treatments with surgery (p=0.864) and radiation (p=0.678). mOS was significantly longer with DTP (17.0 months [95%CI,11.9–22.1]) compared to DT alone (9.0 months [95%CI,4.5–13.5]), p=0.037. mPFS was also significantly improved with DTP as the initial treatment (11.0 months [95%CI,7.0–15.0]) compared to DT alone (4.0 months [95%CI,0.7–7.3]), p=0.049. Twenty-three patients were in the exploratory neoadjuvant group, where mOS was the longest (63.0 months [95%CI,15.5-110.5]). No grade 5 adverse events (AEs) occurred in all three cohorts, and 32.4% had immune-related AEs, most frequently hepatitis and colitis. Conclusions: Our results show that in BRAFm-ATC, addition of pembrolizumab to dabrafenib/trametinib may significantly prolong survival. Surgical resection of the primary tumor after initial BRAF-targeted therapy in selected patients may provide further survival benefit. However, conclusions are limited by the retrospective nature of the study. Additional prospective data are needed to confirm this observation.

Neoadjuvant treatment with lenvatinib and pembrolizumab in a BRAF V600E-mutated anaplastic thyroid cancer: a case report

Combination of Lenvatinib and Pembrolizumab Is an Effective Treatment Option for Anaplastic and Poorly Differentiated Thyroid Carcinoma

Lenvatinib Plus PD-1 Inhibitors As First-Line Treatment in Patients with Unresectable Biliary Tract Cancer: A Single-Arm, Open-Label, Phase II Study

Combination kinase inhibitors and immunotherapy for unresectable anaplastic thyroid carcinoma: A retrospective single-center study

Neoadjuvant Famitinib and Camrelizumab, a New Combined Therapy Allowing Surgical Resection of the Primary Site for Anaplastic Thyroid Carcinoma

Combining BRAF inhibitor and anti PD-L1 antibody dramatically improves tumor regression and anti tumor immunity in an immunocompetent murine model of anaplastic thyroid cancer

First effectiveness data of lenvatinib and pembrolizumab as first-line therapy in advanced anaplastic thyroid cancer: a retrospective cohort study

Combinatorial Hypofractionated Radiotherapy and Pembrolizumab in Anaplastic Thyroid Cancer

Clinical Characteristics, Co-Mutations, and Treatment Outcomes in Advanced Non-Small-Cell Lung Cancer Patients with the BRAF-V600E Mutation

Combination Targeted Therapy with Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers

Initial Management of BRAF V600E-Variant Anaplastic Thyroid Cancer

Salvage Lenvatinib Therapy in Metastatic Anaplastic Thyroid Cancer

Checkpoint Inhibition in Addition to Dabrafenib/Trametinib for BRAF V600E Mutated Anaplastic Thyroid Carcinoma

The Tyrosine Kinase Inhibitor Lenvatinib Inhibits Anaplastic Thyroid Carcinoma Growth by Targeting Pericytes in the Tumor Microenvironment

Advances in targeted therapy for anaplastic thyroid carcinoma

Immunotherapy in anaplastic thyroid cancer: Case series

Anaplastic thyroid cancer: A review of recent evidence and summary of an Australian institutional protocol

Efficacy and safety of BRAF/MEK inhibitors in BRAFV600E-mutated anaplastic thyroid cancer: a systematic review and meta-analysis

Initial Therapy of Advanced Anaplastic Thyroid Cancer Via Targeting VEGFR-2: A Case Report

Dramatic Response to First Line Single Agent Pembrolizumab in Anaplastic Thyroid Carcinoma

Anaplastic Thyroid Cancer Successfully Treated with Radiation and Immunotherapy: A Case Report